Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, stervc, sunspotter, Kylef, Imarket13
Search This Board:
Last Post: 4/27/2015 4:46:00 PM - Followers: 183 - Board type: Free - Posts Today: 17

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Current Report Filing (8-k) 04/14/2015 02:56:21 PM
RCHA News: Statement of Changes in Beneficial Ownership (4) 04/08/2015 05:19:33 PM
RCHA News: Current Report Filing (8-k) 04/08/2015 05:15:13 PM
RCHA News: Current Report Filing (8-k) 04/03/2015 12:00:40 PM
RCHA News: Rich Pharmaceuticals, Inc. Announces Letter of Intent with Faculty of Medicine at Khon Kaen University to Conduct Acute Myelo... 03/24/2015 08:35:00 AM
#7384  Sticky Note $RCHA recent news/filings mick 04/17/15 04:23:21 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#2921  Sticky Note RCHA Expects FDA Orphan Drug Fast Track Approval… stervc 02/07/15 10:05:01 AM
#7554   Yep all L2sare good for QB or higher Catchtwenty2 04/27/15 04:46:00 PM
#7553   VNDM just marked out.... learningthetruth 04/27/15 03:55:16 PM
#7552   Never seen that before on OTC website - ospreyeye 04/27/15 03:41:22 PM
#7551   Why would a T/A verify O/S? tiller 04/27/15 03:37:41 PM
#7550   Possibly bud - the chart is wound tight ospreyeye 04/27/15 03:36:00 PM
#7549   $RCHA - Check this out - RCHA Security ospreyeye 04/27/15 03:32:06 PM
#7548   Too me it looks like dilution is done...but learningthetruth 04/27/15 01:49:28 PM
#7547   Once they stop diluting it should move without Axeman 04/27/15 01:43:02 PM
#7546   IMO. No news this week....mid-May. tiller 04/27/15 09:58:12 AM
#7545   Looks Ready O...get some volume and .002 should learningthetruth 04/27/15 09:43:11 AM
#7544   It's coming the pressure is getting to be PennyStockPower 04/27/15 12:40:39 AM
#7543   RCHA..we are looking at the cusp of a Nadendla 04/27/15 12:40:20 AM
#7542   Looking good this coming week! PennyStockPower 04/27/15 12:39:15 AM
#7541   2 billion is nothing on OTC..Especially with IND Nadendla 04/27/15 12:12:28 AM
#7540   Not by a long shot since that stock Axeman 04/27/15 12:11:13 AM
#7539   This is the time to Buy..believe me.. Nadendla 04/27/15 12:02:04 AM
#7538   Rich Pharmaceuticals Announces Completion of the Manufacture of Nadendla 04/27/15 12:00:13 AM
#7537   why buy what comes here next knrorrel 04/26/15 11:59:48 PM
#7536   Am I looking at another PPCH..:) Nadendla 04/26/15 11:11:34 PM
#7535   RCHA..One NOT to be Ignored..FDA/IND..too close .. Nadendla 04/26/15 11:09:13 PM
#7532   Starting to heat up here durrdurr 04/26/15 10:30:23 AM
#7529   Warning - gross analogy - Exactly - will ospreyeye 04/25/15 12:20:22 PM
#7527   The 1st $Key level to break is 0.0009 ospreyeye 04/25/15 12:03:13 PM
#7526   I've made 10k well nine cause I paid Catchtwenty2 04/24/15 08:37:47 PM
#7525   Thanks! I haven't been called "DUDE" in a long tiller 04/24/15 05:24:48 PM
#7523   I have made 5 grand a few times Stevebb 04/24/15 05:13:00 PM
#7522   Dude there is no way that will happen Maybeismaybenot 04/24/15 05:03:08 PM
#7521   I believe that is exactly what happened before tiller 04/24/15 04:57:58 PM
#7520   5 cents cool_lion 04/24/15 04:56:18 PM
#7519   WHO HERE HAS MADE 5-10K ON ONE TRADE mmtrades5643 04/24/15 04:41:33 PM
#7518   If this does pop, where do you see Maybeismaybenot 04/24/15 04:39:12 PM
#7517   Next Week will be the week for pop! Stock Predictor 04/24/15 03:15:16 PM
#7516   Exactly - checkout today's $Volume - 6M has ospreyeye 04/24/15 01:56:34 PM
#7515   OS unchanged from yesterday morning until today it PennyStockPower 04/24/15 01:54:51 PM
#7514   This can move if the diluting stops. OS Axeman 04/24/15 01:50:52 PM
#7513   $RCHA annotated chart - Fast Sto @ 0.00 ospreyeye 04/24/15 01:41:06 PM
#7512   The notes from March aren't do until Oct. PennyStockPower 04/24/15 10:51:59 AM
#7511   THANKYOU!!! Great information shared. Good eyes. NTTexas 04/24/15 10:17:41 AM
#7510   LOL....The conversions from March still haven't been taken onthegreen 04/24/15 06:15:08 AM
#7509   Did anyone read the 8k from April 14? On scooby3 04/24/15 12:17:24 AM
#7508   Yeah if we can get VNDM ETRF and Catchtwenty2 04/23/15 05:06:30 PM
#7507   7 on the breakout board ! Go RCHA Catchtwenty2 04/23/15 05:01:00 PM
#7506   For me the reason I feel it will PennyStockPower 04/23/15 04:39:44 PM
#7505   What I want to know is how we mmtrades5643 04/23/15 04:16:05 PM
#7500   We clear VNDM it will start to go....add ptcgolf 04/23/15 02:49:19 PM
#7499   Nice~~ Looking for a mark-out here. I think Sooah 04/23/15 02:47:01 PM
#7498   I am not a paid promoter sir. PennyStockPower 04/23/15 02:45:46 PM
#7497   I've taken some of them ptcgolf 04/23/15 02:42:22 PM
#7496   They have a Letter of "Intent" with Khon NTTexas 04/23/15 02:41:36 PM
#7495   Look: VNDM is here showing size at 0008. Sooah 04/23/15 02:39:30 PM